ZY
₹1,184.40
+8.90(+0.76%)
ZYDUSLIFE₹1,184.40+0.76%
Group Companies
Foreign Flows
sector level — not this stockHealthcare sector+₹2,114 Crnet foreign buying
2026-09-01 to 2026-09-15This is the flow into the whole Healthcare sector, not into ZYDUSLIFE. We report it at the level it is measured — attributing a sector figure to one company would be inventing a number nobody published.
Supply Chain
suppliers and customers in the graphMacro Sensitivity
rates, currency, commoditiesRevenue by Segment
Business Group
Geographic Exposure
revenue, imports, currencyScenario analysis
stated assumptions, shown workingsZYDUSLIFE exposure summary
In its latest segment disclosure (Jun 2026), Pharmaceuticals was the largest segment at 78.6% of segment revenue, followed by Consumer products at 17.9%. Zydus Lifesciences Limited is a constituent of 10 indices, with its largest weights in NIFTY Pharma (2.97%), NIFTY Healthcare Index (2.53%), NIFTY Next 50 (1.15%). 20 exchange-traded funds hold the stock.
| Index memberships | 10 |
|---|---|
| ETFs holding | 20 |
| Largest segment | Pharmaceuticals · 78.6% |